Amarin Co. plc (NASDAQ:AMRN) Short Interest Up 20.3% in June

Amarin Co. plc (NASDAQ:AMRN) saw a significant increase in short interest during the month of June. As of June 15th, there was short interest totalling 19,020,000 shares, an increase of 20.3% from the May 31st total of 15,810,000 shares. Based on an average daily trading volume, of 1,490,000 shares, the days-to-cover ratio is currently 12.8 days.

Amarin Stock Down 1.8 %

Shares of Amarin stock opened at $0.69 on Monday. Amarin has a 52 week low of $0.63 and a 52 week high of $1.49. The company has a market capitalization of $282.54 million, a PE ratio of -5.73 and a beta of 1.98. The stock’s fifty day moving average is $0.82 and its two-hundred day moving average is $0.95.

Amarin (NASDAQ:AMRN) last posted its quarterly earnings results on Wednesday, May 1st. The biopharmaceutical company reported ($0.02) EPS for the quarter, topping the consensus estimate of ($0.04) by $0.02. The company had revenue of $56.52 million for the quarter, compared to the consensus estimate of $51.34 million. Amarin had a negative net margin of 18.96% and a negative return on equity of 9.48%. During the same quarter last year, the firm posted ($0.04) EPS. As a group, research analysts anticipate that Amarin will post -0.18 earnings per share for the current year.

Institutional Trading of Amarin

Large investors have recently modified their holdings of the company. Significant Wealth Partners LLC increased its holdings in Amarin by 128.7% during the 1st quarter. Significant Wealth Partners LLC now owns 34,582 shares of the biopharmaceutical company’s stock worth $31,000 after purchasing an additional 19,461 shares during the period. Newbridge Financial Services Group Inc. bought a new stake in shares of Amarin in the first quarter valued at about $37,000. China Universal Asset Management Co. Ltd. raised its holdings in shares of Amarin by 351.7% in the fourth quarter. China Universal Asset Management Co. Ltd. now owns 44,599 shares of the biopharmaceutical company’s stock valued at $39,000 after acquiring an additional 34,725 shares in the last quarter. Vanguard Personalized Indexing Management LLC grew its holdings in Amarin by 100.6% during the 4th quarter. Vanguard Personalized Indexing Management LLC now owns 46,480 shares of the biopharmaceutical company’s stock worth $40,000 after acquiring an additional 23,313 shares in the last quarter. Finally, SVB Wealth LLC grew its holdings in Amarin by 100.0% during the 4th quarter. SVB Wealth LLC now owns 60,000 shares of the biopharmaceutical company’s stock worth $52,000 after acquiring an additional 30,000 shares in the last quarter. Hedge funds and other institutional investors own 22.25% of the company’s stock.

Wall Street Analysts Forecast Growth

AMRN has been the topic of a number of analyst reports. StockNews.com cut shares of Amarin from a “buy” rating to a “hold” rating in a research report on Tuesday, June 25th. Cantor Fitzgerald reiterated an “overweight” rating on shares of Amarin in a report on Tuesday, June 18th. Two equities research analysts have rated the stock with a sell rating, two have given a hold rating and one has issued a buy rating to the company. Based on data from MarketBeat, Amarin presently has an average rating of “Hold” and an average price target of $1.08.

Amarin Company Profile

Amarin Corporation plc, a pharmaceutical company, engages in the development and commercialization of therapeutics for the treatment of cardiovascular diseases in the United States, European countries, Canada, Lebanon, and the United Arab Emirates. The company offers VASCEPA, a prescription-only omega-3 fatty acid product, used as an adjunct to diet for reducing triglyceride levels in adult patients with severe hypertriglyceridemia.